Literature DB >> 11146437

High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases.

G Chiappetta1, G Manfioletti, F Pentimalli, N Abe, M Di Bonito, M T Vento, A Giuliano, M Fedele, G Viglietto, M Santoro, T Watanabe, V Giancotti, A Fusco.   

Abstract

HMGI(Y) proteins are overexpressed in experimental and human malignancies, including colon, prostate and thyroid carcinomas. To determine at which step of the carcinogenic process HMGI(Y) induction occurs, we analysed the expression of the HMGI(Y) proteins in hyperplastic, preneoplastic and neoplastic tissues of colorectal origin by immunohistochemistry. All the colorectal carcinomas were HMGI(Y)-positive, whereas no expression was detected in normal colon mucosa tissue. HMGI(Y) expression in adenomas was closely correlated with the degree of cellular atypia. Only 2 of the 18 non-neoplastic polyps tested were HMGI(Y)-positive. These data indicate that HMGI(Y) protein induction is associated with the early stages of neoplastic transformation of colon cells and only rarely with colon cell hyperproliferation. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11146437     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1033>3.3.co;2-m

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

Review 2.  High mobility group proteins and their post-translational modifications.

Authors:  Qingchun Zhang; Yinsheng Wang
Journal:  Biochim Biophys Acta       Date:  2008-05-10

Review 3.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

Review 4.  Polycomb protein family member CBX7 plays a critical role in cancer progression.

Authors:  Pierlorenzo Pallante; Floriana Forzati; Antonella Federico; Claudio Arra; Alfredo Fusco
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 5.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

6.  Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer.

Authors:  Ze Zhang; Quan Wang; Feng Chen; Jun Liu
Journal:  Tumour Biol       Date:  2014-10-25

7.  Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.

Authors:  Gustavo Baldassarre; Sabrina Battista; Barbara Belletti; Sanjay Thakur; Francesca Pentimalli; Francesco Trapasso; Monica Fedele; Giovanna Pierantoni; Carlo M Croce; Alfredo Fusco
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  High-mobility group A1 proteins are overexpressed in human leukaemias.

Authors:  Giovanna Maria Pierantoni; Valter Agosti; Monica Fedele; Heather Bond; Irene Caliendo; Gennaro Chiappetta; Francesco Lo Coco; Fabrizio Pane; Maria Caterina Turco; Giovanni Morrone; Salvatore Venuta; Alfredo Fusco
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

9.  Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis.

Authors:  Massimiliano Mellone; Christian Rinaldi; Isabella Massimi; Marialaura Petroni; Veronica Veschi; Claudio Talora; Silvia Truffa; Helena Stabile; Luigi Frati; Isabella Screpanti; Alberto Gulino; Giuseppe Giannini
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  HMGI(Y) gene expression as a potential marker of thyroid follicular carcinoma.

Authors:  W Czyz; E Balcerczak; M Jakubiak; Z Pasieka; K Kuzdak; M Mirowski
Journal:  Langenbecks Arch Surg       Date:  2004-04-24       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.